RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jose L. Lopez-Ribot to Echinocandins

This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Echinocandins.
Connection Strength

1.613
  1. Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother. 2014; 58(2):1183-6.
    View in: PubMed
    Score: 0.469
  2. Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother. 2011 Jul; 55(7):3591-3.
    View in: PubMed
    Score: 0.393
  3. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother. 2009 Sep; 64(3):567-70.
    View in: PubMed
    Score: 0.347
  4. Uppuluri P, Dinakaran H, Thomas DP, Chaturvedi AK, Lopez-Ribot JL. Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J Clin Microbiol. 2009 Dec; 47(12):4078-83.
    View in: PubMed
    Score: 0.088
  5. Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, L?pez-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother. 2003 Nov; 47(11):3657-9.
    View in: PubMed
    Score: 0.059
  6. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, L?pez-Ribot JL. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002 Nov; 46(11):3591-6.
    View in: PubMed
    Score: 0.055
  7. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, L?pez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2002 Nov; 46(11):3634-6.
    View in: PubMed
    Score: 0.055
  8. Bachmann SP, Patterson TF, L?pez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002 Jun; 40(6):2228-30.
    View in: PubMed
    Score: 0.053
  9. Srinivasan A, Gupta CM, Agrawal CM, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms. Biotechnol Bioeng. 2014 Feb; 111(2):418-24.
    View in: PubMed
    Score: 0.029
  10. Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 2011 Sep; 7(9):e1002257.
    View in: PubMed
    Score: 0.025
  11. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 2012 Jan; 55(1):80-5.
    View in: PubMed
    Score: 0.025
  12. Hernandez S, L?pez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004 Apr; 48(4):1382-3.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support